Which basal insulin should be used in patients with type 2 diabetes mellitus?

被引：6

作者：

Clore J.N. ^{[1
]}

Thurby-Hay L. ^{[1
]}

机构：

[1] Division of Endocrinology and Metabolism, Virginia Commonwealth University, Richmond, VA 23298

来源：

Current Diabetes Reports | 2007年 / 7卷 / 5期

关键词：

Insulin Glargine; Basal Insulin; Insulin Lispro; Insulin Detemir; Endogenous Glucose Production;

D O I：

10.1007/s11892-007-0057-8

中图分类号：

学科分类号：

摘要：

The initiation of insulin therapy is a significant event for patients with diabetes and the physicians who care for them. Reluctance to begin insulin is multifactorial, with major stumbling blocks being the perceived complexity of insulin and fear of hypoglycemia. Recent guidelines supporting earlier introduction of insulin to achieve glycemic goals in patients with type 2 diabetes mellitus will require that traditional approaches to insulin therapy be altered and a new paradigm be introduced into clinical practice. In particular, an understanding of the role of basal insulin in the regulation of glucose and the development of strategies to implement basal insulin therapy can provide a transition that is rational and highly effective in most patients. The strategy also offers a unique approach to diabetes education that permits a focused and patient-specific correction to glucose abnormalities. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：348 / 352

页数：4

共 27 条

[1]

Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group [no authors listed], Lancet, 352, pp. 837-853, (1998)

[2]

Effect of intensive blood glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study Group [no authors listed], Lancet, 352, pp. 854-865, (1998)

[3]

The Diabetes Control and Complications Trial Research Group [no authors listed], N Engl J Med, 329, pp. 977-986, (1993)

[4]

Polonsky K.S., Licinio-Paixao J., Given B.D., Et al., Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients, J Clin Invest, 77, pp. 98-105, (1986)

[5]

DeFronzo R.A., Bonadonna R.C., Ferrannini E., Pathogenesis of NIDDM. A balanced overview, Diabetes Care, 15, pp. 318-368, (1992)

[6]

Boden G., Cheung P., Homko C., Effects of acute insulin excess and deficiency on gluconeogenesis and glycogenolysis in type 1 diabetes, Diabetes, 52, pp. 133-137, (2003)

[7]

Rebrin K., Steil G.M., Getty L., Et al., Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin, Diabetes, 44, pp. 1038-1045, (1995)

[8]

Clore J.N., Glickman P.S., Nestler J.E., Et al., In vivo evidence for hepatic autoregulation during FFA-stimulated gluconeogenesis in normal humans, Am J Physiol, 261, (1991)

[9]

Boden G., Effects of free fatty acids on gluconeogenesis and glycogenolysis, Life Sci, 72, pp. 977-988, (2003)

[10]

Boden G., Chen X., Capulong E., Et al., Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes, Diabetes, 50, pp. 810-816, (2001)

← 1 2 3 →